Joseph Haas
Senior writer
Senior writer
Maryland, USA
15+ years of experience
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Joseph Haas 17 Jan 2022
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Joseph Haas 01 Oct 2021
Merck/Ridgeback’s ribonucleoside analog shows nearly 50% reduction of risk for hospitalization or death in Phase III study. Firms will seek EUA in US; a contract is in place for 1.7 million courses of therapy.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Joseph Haas 26 Feb 2021
Looking back at the deal landscape of 2020, large-scale deals were overtaken by smaller transactions, though volume was up, driven by pandemic-related business.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Joseph Haas 27 Nov 2020
With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.
Topic Coronavirus
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Joseph Haas 27 Nov 2020
The pharma and the Google spinout focused on aging are adding $1bn in funding to their 2014 collaboration, which has yielded more than two dozen preclinical candidates so far.
Topic Alzheimer's Disease
世界の薬事規制動向＆情報を配信
By Joseph Haas 29 Oct 2020
EUA request for COVID-19 vaccine is unlikely before late November; the CEO’s frequent comments that the timetable isn’t politically motivated are unusual to say the least
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Joseph Haas 03 Jun 2020
Remdesivir shows ability to yield clinical improvement in moderately ill COVID-19 patients, but data are called ‘modest’ and shorter therapy duration showed better results than longer.
Topic Coronavirus Clinical Trials
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Joseph Haas 01 May 2020
With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Joseph Haas 20 Apr 2020
Big pharma stocks, with few exceptions, saw big declines in valuation in the quarter amid the COVID-19 stock market rollercoaster, but pharma outperformed the S&P 500, showing the industry's resiliency in a global health crisis.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Joseph Haas 06 Apr 2020
The companies are combining their technologies to seek neutralizing antibody therapeutics that could prevent or treat COVID-19, building on their previous partnership in monitoring minimal residual disease in blood cancers.
Topic Coronavirus
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Joseph Haas 27 Mar 2020
AlloVir/Baylor, Soligenix/Hawaii and CEL-SCI/Georgia ink coronavirus collaborations, but deal-making continues in other areas as well, including Asklepios/UNC teaming on a gene therapy for Angelman syndrome and DeMelle licensing a targeted pancreatic cancer drug from Moffitt, among others.
Topic Coronavirus Medtech
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Joseph Haas 15 Jan 2020
Biktarvy’s powerful sales growth and the potential of a first-in-class capsid inhibitor in both prevention and heavily treatment-experienced patients are key to Gilead’s plan for staying on top in HIV.
Topic Business Strategies Infectious Diseases Life Cycle Management
ターゲット市場の実像をつかむ
By Joseph Haas 05 Nov 2019
NASH（非アルコール性脂肪性肝炎）はさらに大きな流行病となりつつあり、あらゆる規模の企業が、業界初のNASH治療薬を市場に出すためにしのぎを削っています。新薬および転用された新薬探索、NASHの治療に関する詳細なディスカッション、およびこの分野のディールメイキング、ライセンスシング、提携戦略についてお聞きください。
Topic Cell & Gene Therapy Drug Development Landscape Approvals
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Joseph Haas 11 Sep 2019
The Medicines Co. unveiled Phase III safety data for inclisiran showing safety and tolerability comparable to placebo and efficacy in line with the PCSK9 inhibitor class – which should be the reassurance it needs for the oral agent.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Joseph Haas 03 Jul 2019
Looking back at the second quarter, PharmaVitae analysts have selected 10 biopharma companies with market caps under $3bn they think are primed for acquisition – and the likely candidates for a buy-out.
Scrip: 世界の医療用医薬品＆製薬産...
22 Jul 2022
Scrip: 世界の医療用医薬品＆製薬産...
21 Jul 2022
Scrip: 世界の医療用医薬品＆製薬産...
20 Jul 2022
Scrip: 世界の医療用医薬品＆製薬産...
19 Jul 2022
In Vivo: 医療用医薬品・医療機器...
11 Jul 2022
Scrip: 世界の医療用医薬品＆製薬産...
05 Jul 2022
Scrip: 世界の医療用医薬品＆製薬産...
01 Jul 2022
Scrip: 世界の医療用医薬品＆製薬産...
28 Jun 2022
Scrip: 世界の医療用医薬品＆製薬産...
28 Jun 2022
Scrip: 世界の医療用医薬品＆製薬産...
24 Jun 2022
Scrip: 世界の医療用医薬品＆製薬産...
24 Jun 2022
Scrip: 世界の医療用医薬品＆製薬産...
23 Jun 2022
Scrip: 世界の医療用医薬品＆製薬産...
22 Jun 2022
Scrip: 世界の医療用医薬品＆製薬産...
17 Jun 2022
Scrip: 世界の医療用医薬品＆製薬産...
16 Jun 2022
